Continuation of lithium after a diagnosis of chronic kidney disease.
Saved in:
| Title: | Continuation of lithium after a diagnosis of chronic kidney disease. |
|---|---|
| Authors: | Kessing, L. V., Feldt‐Rasmussen, B., Andersen, P. K., Gerds, T. A., Licht, R. W. |
| Source: | Acta Psychiatrica Scandinavica. Dec2017, Vol. 136 Issue 6, p615-622. 8p. 2 Charts, 2 Graphs. |
| Subjects: | Therapeutic use of lithium, Chronic kidney failure, Anticonvulsants, Bipolar disorder, Therapeutics research |
| Abstract: | Objective To investigate whether continued lithium or anticonvulsant treatment after a first diagnosis of chronic kidney disease ( CKD) was associated with progression to irreversible end-stage kidney disease. Methods Nationwide cohort study including all individuals in Denmark in a period from 1995 to 2012 with a diagnosis of CKD and (i) a history of lithium treatment ( N = 754, among whom 238 patients had a diagnosis of bipolar disorder) or (ii) a history of anticonvulsant treatment ( N = 5.004, among whom 199 patients had a diagnosis of bipolar disorder). End-stage CKD was defined as chronic dialysis or renal transplantation. Results Continuing lithium ( HR = 0.58 (95% CI: 0.37-0.90) and continuing anticonvulsants ( HR = 0.53 (95% CI: 0.44-0.64) were associated with decreased rates of end-stage CKD. In the subcohorts of patients with a diagnosis of bipolar disorder, continuing lithium was associated with decreased end-stage CKD ( HR = 0.40 (95% CI: 0.17-0.98), whereas continuing anticonvulsants was not ( HR = 0.70 (95% CI: 0.21-2.37). There were no interactions of continuing lithium and anticonvulsants. Conclusion After an initial diagnosis of CKD, patients who are selected by their physicians to continue lithium treatment may not necessarily have an increased risk of developing end-stage CKD. Shifting to an anticonvulsant per se may not be associated with an advantage; however, this requires further investigation. [ABSTRACT FROM AUTHOR] |
| Copyright of Acta Psychiatrica Scandinavica is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Psychology and Behavioral Sciences Collection |
| FullText | Links: – Type: pdflink Text: Availability: 0 |
|---|---|
| Header | DbId: pbh DbLabel: Psychology and Behavioral Sciences Collection An: 126068646 AccessLevel: 6 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Continuation of lithium after a diagnosis of chronic kidney disease. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Kessing%2C+L%2E+V%2E%22">Kessing, L. V.</searchLink><br /><searchLink fieldCode="AR" term="%22Feldt‐Rasmussen%2C+B%2E%22">Feldt‐Rasmussen, B.</searchLink><br /><searchLink fieldCode="AR" term="%22Andersen%2C+P%2E+K%2E%22">Andersen, P. K.</searchLink><br /><searchLink fieldCode="AR" term="%22Gerds%2C+T%2E+A%2E%22">Gerds, T. A.</searchLink><br /><searchLink fieldCode="AR" term="%22Licht%2C+R%2E+W%2E%22">Licht, R. W.</searchLink> – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22Acta+Psychiatrica+Scandinavica%22">Acta Psychiatrica Scandinavica</searchLink>. Dec2017, Vol. 136 Issue 6, p615-622. 8p. 2 Charts, 2 Graphs. – Name: Subject Label: Subjects Group: Su Data: <searchLink fieldCode="DE" term="%22Therapeutic+use+of+lithium%22">Therapeutic use of lithium</searchLink><br /><searchLink fieldCode="DE" term="%22Chronic+kidney+failure%22">Chronic kidney failure</searchLink><br /><searchLink fieldCode="DE" term="%22Anticonvulsants%22">Anticonvulsants</searchLink><br /><searchLink fieldCode="DE" term="%22Bipolar+disorder%22">Bipolar disorder</searchLink><br /><searchLink fieldCode="DE" term="%22Therapeutics+research%22">Therapeutics research</searchLink> – Name: Abstract Label: Abstract Group: Ab Data: Objective To investigate whether continued lithium or anticonvulsant treatment after a first diagnosis of chronic kidney disease ( CKD) was associated with progression to irreversible end-stage kidney disease. Methods Nationwide cohort study including all individuals in Denmark in a period from 1995 to 2012 with a diagnosis of CKD and (i) a history of lithium treatment ( N = 754, among whom 238 patients had a diagnosis of bipolar disorder) or (ii) a history of anticonvulsant treatment ( N = 5.004, among whom 199 patients had a diagnosis of bipolar disorder). End-stage CKD was defined as chronic dialysis or renal transplantation. Results Continuing lithium ( HR = 0.58 (95% CI: 0.37-0.90) and continuing anticonvulsants ( HR = 0.53 (95% CI: 0.44-0.64) were associated with decreased rates of end-stage CKD. In the subcohorts of patients with a diagnosis of bipolar disorder, continuing lithium was associated with decreased end-stage CKD ( HR = 0.40 (95% CI: 0.17-0.98), whereas continuing anticonvulsants was not ( HR = 0.70 (95% CI: 0.21-2.37). There were no interactions of continuing lithium and anticonvulsants. Conclusion After an initial diagnosis of CKD, patients who are selected by their physicians to continue lithium treatment may not necessarily have an increased risk of developing end-stage CKD. Shifting to an anticonvulsant per se may not be associated with an advantage; however, this requires further investigation. [ABSTRACT FROM AUTHOR] – Name: AbstractSuppliedCopyright Label: Group: Ab Data: <i>Copyright of Acta Psychiatrica Scandinavica is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.) |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=126068646 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1111/acps.12820 Languages: – Code: eng Text: English PhysicalDescription: Pagination: PageCount: 8 StartPage: 615 Subjects: – SubjectFull: Therapeutic use of lithium Type: general – SubjectFull: Chronic kidney failure Type: general – SubjectFull: Anticonvulsants Type: general – SubjectFull: Bipolar disorder Type: general – SubjectFull: Therapeutics research Type: general Titles: – TitleFull: Continuation of lithium after a diagnosis of chronic kidney disease. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Kessing, L. V. – PersonEntity: Name: NameFull: Feldt‐Rasmussen, B. – PersonEntity: Name: NameFull: Andersen, P. K. – PersonEntity: Name: NameFull: Gerds, T. A. – PersonEntity: Name: NameFull: Licht, R. W. IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 12 Text: Dec2017 Type: published Y: 2017 Identifiers: – Type: issn-print Value: 0001690X Numbering: – Type: volume Value: 136 – Type: issue Value: 6 Titles: – TitleFull: Acta Psychiatrica Scandinavica Type: main |
| ResultId | 1 |
